111 related articles for article (PubMed ID: 35636408)
1. EMT-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Hepatocellular Carcinoma.
Cao D; Liu H; Bai L; Tang H
Dig Dis; 2023; 41(2):282-295. PubMed ID: 35636408
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
Chen S; Zhao E
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
5. Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma.
Tao H; Zhang Y; Yuan T; Li J; Liu J; Xiong Y; Zhu J; Huang Z; Wang P; Liang H; Zhang E
Aging (Albany NY); 2022 Feb; 14(3):1473-1491. PubMed ID: 35148283
[TBL] [Abstract][Full Text] [Related]
6. A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma.
Shi Y; Wang J; Huang G; Zhu J; Jian H; Xia G; Wei Q; Li Y; Yu H
Hepatol Int; 2022 Aug; 16(4):906-917. PubMed ID: 35699863
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of epithelial mesenchymal transition-related prognostic model for hepatocellular carcinoma.
Wang X; Xing Z; Xu H; Yang H; Xing T
Aging (Albany NY); 2021 Apr; 13(10):13822-13845. PubMed ID: 33929972
[TBL] [Abstract][Full Text] [Related]
8. A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes.
Xiong C; Wang G; Bai D
Bioengineered; 2020 Dec; 11(1):1034-1046. PubMed ID: 32951492
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
10. An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients.
Zhu G; Xia H; Tang Q; Bi F
Cancer Cell Int; 2021 Mar; 21(1):166. PubMed ID: 33712026
[TBL] [Abstract][Full Text] [Related]
11. Identification of Epithelial Mesenchymal Transition-Related lncRNAs Associated with Prognosis and Tumor Immune Microenvironment of Hepatocellular Carcinoma.
Zhou Y; Wang L; Zhang W; Ma J; Zhang Z; Yang M; Yu J; Luo J; Yan Z
Dis Markers; 2022; 2022():6335155. PubMed ID: 35111268
[TBL] [Abstract][Full Text] [Related]
12. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma.
Zhang X; Ma L; Zhai L; Chen D; Li Y; Shang Z; Zhang Z; Gao Y; Yang W; Li Y; Pan Y
Int J Med Sci; 2021; 18(4):984-999. PubMed ID: 33456356
[TBL] [Abstract][Full Text] [Related]
13. Seven-senescence-associated gene signature predicts overall survival for Asian patients with hepatocellular carcinoma.
Xiang XH; Yang L; Zhang X; Ma XH; Miao RC; Gu JX; Fu YN; Yao Q; Zhang JY; Liu C; Lin T; Qu K
World J Gastroenterol; 2019 Apr; 25(14):1715-1728. PubMed ID: 31011256
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Novel Epithelial-to-mesenchymal-related Gene Signature in Predicting Survival of Patients with Hepatocellular Carcinoma.
Xiao S; Hu J; Hu N; Sheng L; Rao H; Zheng G
Comb Chem High Throughput Screen; 2022; 25(8):1254-1270. PubMed ID: 33655854
[TBL] [Abstract][Full Text] [Related]
15. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
[TBL] [Abstract][Full Text] [Related]
16. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
18. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
19. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
20. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
